Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

By sjmartinez • September 24, 2024

André F, Solovieff N, Su F, Bardia A, Neven P, Yap YS, Tripathy D, Lu YS, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga CL. Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. Ann Oncol. 2024 Sep 21:S0923-7534(24)04018-3. doi: 10.1016/j.annonc.2024.09.010. Epub ahead of print. PMID: 39313156.

Tags: acquired resistance, Advanced breast cancer, biomarkers, CDK4/6 inhibitor, Hematology/Oncology, Publications, ribociclib

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]

Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

Valentín López JC, Ho A, Hughes KS, Bardia A, Vidula N. Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from[...]

PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in pancreatic cancer

Kim KJ, Lee CH, Nam M, Na HY, Sung JH, Park BR, Hwang SH, Park W, Seo J, Kang M, Jung EH, Kim SA, Suh[...]